However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
House Republicans reported “very positive developments” after a marathon meeting at the White House on Thursday focused on ...
Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Merus (MRUS) with an Overweight rating and $91 price target The firm thinks ...
How Tech Billionaires on the Right Bought the Loudest Voices on the Left," discusses how tech billionaires changed the media ...